Efficacy and Safety of Chinese Herbal Formula Granules in Treating Chronic Kidney Disease Stage 3: A Multicenter, Randomized, Placebo-Controlled, Double-Blind Clinical Trial

Table 6

Change from baseline in serum creatinine over the 24-week follow-up period.

Time	Treatment group	Control group	Effect	F value	value
Pretreatment (μmol/L)	148.42 ± 35.90	147.26 ± 28.71	Time effect	3.11	0.0086
Week 4 (μmol/L)	138.80 ± 31.62	148.06 ± 34.99	Difference between groups	54.69	0.0001
Week 8 (μmol/L)	133.28 ± 30.95	150.22 ± 36.70
Week 12 (μmol/L)	132.59 ± 30.42	147.73 ± 39.02
Week 16 (μmol/L)	130.19 ± 29.79	150.50 ± 38.23
Week 20 (μmol/L)	130.08 ± 30.57	151.10 ± 36.18
Week 24 (μmol/L)	130.78 ± 32.55	149.12 ± 41.27

Compared with pretreatment, the difference was significant in the treatment group,  < 0.05.